Incretin-Based Drugs Market Outlook, Oral GLP-1 Competition, Access Trends and Forecast to 2035

Incretin-Based Drugs Market Overview

The global Incretin-Based Drugs Market reached US$28.18 billion in 2025 and is expected to reach US$48.63 billion by 2035, growing at a CAGR of 5.6% during the forecast period 2026–2035.

Key Takeaways

• The global incretin-based drugs market was valued at US$28.18 billion in 2025.
• The market is forecast to reach US$48.63 billion by 2035.
• Market revenue is expected to grow at a CAGR of 5.6% from 2026 to 2035.
• Injectable peptide therapies currently form the largest commercial segment because of established products containing semaglutide, tirzepatide, dulaglutide and other GLP-1-based molecules.
• Oral therapies are expected to record faster growth as Wegovy tablets and Foundayo establish the first large-scale commercial market for oral obesity medicines.
• The oral market is dividing into peptide formulations and non-peptide small molecules, which differ in absorption, administration, manufacturing and distribution requirements.
• Obesity and chronic weight management are expected to be the fastest-expanding indication group.
• Type 2 diabetes remains a foundational market supported by GLP-1 receptor agonists, dual agonists and DPP-4 inhibitors.
• Public and commercial payer coverage will have a greater effect on realized demand than regulatory approval alone.
• The Medicare GLP-1 Bridge represents a major 2026 US access development, providing eligible beneficiaries with designated weight-management GLP-1 medicines at a stated monthly cost of US$50.
• Novo Nordisk and Eli Lilly hold the strongest approved-product positions, while Roche, Boehringer Ingelheim, Amgen, Structure Therapeutics, Viking Therapeutics and Innovent Biologics are advancing differentiated incretin pipelines.
• Manufacturing competition is separating into two models: high-volume peptide and injectable-device production, and scalable small-molecule oral solid-dose manufacturing.
• Combination therapies targeting GLP-1 alongside GIP, glucagon, amylin or other metabolic pathways are expected to become a larger part of the development pipeline.

Market Scope

2026 Official Developments Reshaping the Incretin-Based Drugs Market

Wegovy Pill Establishes a Commercial Oral Obesity Market

Novo Nordisk launched the Wegovy semaglutide pill in the United States in January 2026 following its FDA approval as an oral GLP-1 receptor agonist for chronic weight management. The commercial introduction marked an important expansion of incretin therapy beyond weekly injectable products and created a new competitive category for patients seeking oral weight-management treatment.

By June 2026, Novo Nordisk reported that Wegovy pill prescriptions had surpassed three million in the United States. The company also reported that the product had reached more than one million people by April 2026, indicating rapid early uptake across self-pay, retail and other commercial channels.

On July 15, 2026, Novo Nordisk received European Commission approval for the Wegovy pill as the first oral GLP-1 treatment for weight management in the European Union. The approval followed a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use in May 2026.

The oral Wegovy launch demonstrates that peptide-based incretin medicines can compete in the tablet market. However, oral semaglutide remains a peptide formulation with administration instructions intended to support absorption, distinguishing it from emerging non-peptide small-molecule GLP-1 receptor agonists.

FDA Approves Lilly’s Small-Molecule Oral GLP-1

On April 1, 2026, the US FDA approved Eli Lilly’s Foundayo, or orforglipron, for adults with obesity or overweight accompanied by at least one weight-related medical condition.

Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist administered once daily. Unlike oral peptide GLP-1 formulations, it can be taken without food or water-timing restrictions. The product became available through LillyDirect, telehealth providers and US retail pharmacies in April 2026.

The approval created direct competition between two oral incretin models:

• A peptide-based oral semaglutide formulation
• A chemically synthesized, non-peptide small-molecule GLP-1 receptor agonist

This competition is expected to reshape prescribing patterns, manufacturing requirements, distribution channels and payer negotiations across the obesity market.

Medicare GLP-1 Bridge Expands US Access

The Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge on July 1, 2026. The short-term demonstration provides qualifying Medicare Part D beneficiaries with access to selected GLP-1 medicines for weight management at a stated monthly cost of US$50.

The program operates outside the conventional Medicare Part D coverage and payment process and is scheduled to remain available through December 31, 2027. Eligible products include designated formulations of Wegovy, Foundayo and Zepbound.

The bridge represents a significant change in the US market because Medicare has historically provided limited coverage for medicines used solely for weight reduction. It also illustrates how future market growth will depend on payer-defined eligibility, prior authorization and negotiated patient costs rather than regulatory approval alone.

Lilly Invests in Next-Generation Injectable Capacity

In January 2026, Eli Lilly announced plans to invest more than US$3.5 billion in a new injectable medicine and device manufacturing facility in Pennsylvania.

The facility is expected to support next-generation weight-management therapies, including retatrutide, Lilly’s investigational triple agonist targeting GIP, GLP-1 and glucagon receptors.

This investment highlights the continuing need for:

• Peptide active pharmaceutical ingredient capacity
• Sterile fill-and-finish operations
• Injection-device assembly
• Quality-control laboratories
• High-volume packaging
• Supply-chain redundancy

Even as oral GLP-1 medicines expand, injectable products are expected to remain central to the market because of their established efficacy, weekly administration and growing role in obesity-related complications.

Roche Advances Dual-Agonist and Oral Small-Molecule Programs

Roche presented new Phase II information on its obesity pipeline at the American Diabetes Association’s 2026 Scientific Sessions.

Its portfolio includes enicepatide, formerly CT-388, an investigational injectable dual GLP-1/GIP receptor agonist, and CT-996, an investigational once-daily oral small-molecule GLP-1 receptor agonist. Roche is evaluating enicepatide across obesity and type 2 diabetes populations while continuing the clinical development of CT-996.

The combination of oral and injectable programs gives Roche multiple routes into the incretin-based market and supports a portfolio strategy centered on treatment personalization, combination therapy and differentiated dosing.

Multi-Receptor Programs Move Closer to Commercial Readiness

Boehringer Ingelheim reported positive Phase III results for survodutide, an injectable dual glucagon and GLP-1 receptor agonist. The SYNCHRONIZE-1 study met its primary endpoints and reported sustained weight reduction in adults with obesity or overweight without type 2 diabetes.

Structure Therapeutics reported Phase IIb data for aleniglipron, an oral small-molecule GLP-1 receptor agonist, and stated that its Phase III program remained scheduled to begin in the third quarter of 2026.

Viking Therapeutics is developing VK2735, a dual GIP and GLP-1 receptor agonist, in both oral and subcutaneous formulations. Its injectable formulation has entered a Phase III development program, while the oral formulation remains under clinical investigation.

These developments demonstrate that future competition will extend beyond single-receptor GLP-1 agonism. Developers are combining incretin and metabolic pathways to pursue stronger weight reduction, better glycaemic control, differentiated body-composition outcomes and broader cardiometabolic benefits.

Market Outlook

The incretin-based drugs market is undergoing a structural transition from a diabetes-centered market dominated by injectable GLP-1 receptor agonists and oral DPP-4 inhibitors into a broader cardiometabolic market spanning obesity, cardiovascular risk, sleep apnoea, metabolic liver disease and other weight-related complications.

Commercial competition is increasingly organized around four strategic questions:

• Can the treatment provide clinically meaningful and durable outcomes?
• Can patients start and remain on treatment?
• Can manufacturers produce sufficient volumes at a sustainable cost?
• Will public or private payers provide predictable reimbursement?

The launch of oral obesity medicines adds a fifth question: whether patients and prescribers will prefer daily tablets over weekly injections when efficacy, tolerability, cost and administration requirements are considered together.

The market is expected to add approximately US$20.45 billion in revenue between 2025 and 2035. Growth will be driven by a combination of increasing treatment volumes, broader indications, improved access and the introduction of new oral and multi-receptor medicines.

However, expansion will be moderated by pricing pressure, payer controls, competition between branded products, genericization of mature DPP-4 inhibitors, treatment discontinuation and increasing scrutiny of long-term affordability.

Market Size and Forecast

Recommended chart title: Global Incretin-Based Drugs Market Size, 2025 and 2035

• Market size in 2025: US$28.18 billion
• Forecast market size in 2035: US$48.63 billion
• Absolute market expansion: US$20.45 billion
• CAGR during 2026–2035: 5.6%
• Base year: 2025
• Historical period: 2023–2024
• Forecast period: 2026–2035
• Available data period: 2023–2035

The forecast reflects strong underlying patient demand but also recognizes that rapid prescription growth will not translate directly into unrestricted revenue expansion.

Payer negotiations, volume-linked pricing, competitive discounting and the launch of oral alternatives are expected to influence average realized prices. Mature diabetes treatments will also face generic competition, while higher-value obesity and multi-receptor medicines account for an increasing share of market growth.

Market Definition and Research Scope

Incretin-based drugs are medicines that directly or indirectly enhance the physiological activity of incretin hormones, principally GLP-1 and GIP.

The incretin system helps regulate glucose-dependent insulin secretion, glucagon activity, appetite, gastric emptying and energy intake. Modern medicines increasingly use these pathways not only for glycaemic control but also for chronic weight management and related metabolic conditions.

Included in the Market

• GLP-1 receptor agonists
• GIP and GLP-1 dual receptor agonists
• Glucagon and GLP-1 dual receptor agonists
• GIP, GLP-1 and glucagon triple agonists
• Other multi-receptor incretin agonists
• Oral peptide GLP-1 receptor agonists
• Oral non-peptide small-molecule GLP-1 receptor agonists
• DPP-4 inhibitors
• Fixed-dose combinations containing an incretin-based medicine
• Approved injectable and oral medicines
• Commercially marketed branded and generic products

Pipeline Coverage

The report analyzes clinical-stage products by:

• Mechanism of action
• Molecular format
• Administration route
• Development phase
• Target indication
• Sponsor
• Combination strategy
• Expected competitive position

Pipeline products are evaluated in the competitive analysis but are not included in current market revenue until they receive approval and enter commercial distribution.

Excluded From the Core Market

• Insulin-only medicines
• SGLT2 inhibitors without an incretin component
• Standalone amylin analogues
• Conventional appetite suppressants
• Bariatric procedures
• Nutritional supplements
• Unapproved compounded semaglutide or tirzepatide products
• Research chemicals without a regulated clinical-development program
• Medicines used entirely outside approved or recognized commercial channels

Peptide Versus Small-Molecule Incretin Drugs

The arrival of oral small-molecule GLP-1 receptor agonists requires the market to be analyzed by molecular format rather than by route of administration alone.

Peptide-Based Incretin Medicines

Peptide incretin medicines are designed from, or engineered to reproduce, the activity of naturally occurring metabolic hormones.

Examples include:

• Semaglutide
• Tirzepatide
• Dulaglutide
• Liraglutide
• Survodutide
• Retatrutide
• Enicepatide
• VK2735

Peptide therapies can activate one or multiple metabolic receptors with high selectivity. Most commercial peptide therapies are administered by subcutaneous injection, although oral semaglutide demonstrates that peptide molecules can also be formulated as tablets.

The principal manufacturing requirements may include:

• Peptide synthesis or biologically supported active-ingredient production
• Purification
• Sterile formulation for injectable products
• Fill-and-finish capacity
• Pen or autoinjector assembly
• Device-component supply
• Temperature-controlled distribution
• Complex analytical testing

Oral peptide products eliminate injection-device requirements but retain peptide-production complexity and must overcome poor gastrointestinal absorption.

Non-Peptide Small-Molecule GLP-1 Agonists

Non-peptide GLP-1 receptor agonists are chemically synthesized molecules designed to activate the GLP-1 receptor without using a peptide structure.

Examples include:

• Orforglipron
• CT-996
• Aleniglipron

Small molecules can potentially be manufactured using conventional chemical active-ingredient and oral solid-dose processes. They may also offer easier storage, distribution and large-scale tablet production than injectable peptide products.

Foundayo’s US prescribing information allows once-daily oral use without food or water-timing restrictions, providing a differentiated administration profile.

Commercial success will nevertheless depend on more than convenience. Small-molecule products must demonstrate competitive efficacy, gastrointestinal tolerability, long-term safety, adherence and payer acceptance.

Oral Peptide Versus Oral Small Molecule

Oral semaglutide and orforglipron represent two different commercial approaches.

Oral peptide products:

• Use an engineered peptide active ingredient
• Require formulation technology that supports gastrointestinal absorption
• May have specific fasting, water or medication-timing instructions
• Build on an established molecule with extensive clinical experience
• May require comparatively high active-ingredient quantities per tablet

Oral small-molecule products:

• Use chemically synthesized non-peptide active ingredients
• Can potentially be manufactured through conventional tablet processes
• May offer simpler administration
• Create new intellectual-property and manufacturing pathways
• Require their own long-term safety and outcome evidence

Neither format will automatically replace injectable therapy. Market share will depend on the balance among efficacy, tolerability, convenience, dosing frequency, cost and insurance coverage.

Market Dynamics

Oral GLP-1 Medicines Expand the Addressable Patient Population

Some patients delay or avoid treatment because they do not want to use injectable medicines. Oral products may lower this initiation barrier and allow incretin therapy to reach patients earlier in the treatment pathway.

The January 2026 US launch of Wegovy tablets and April 2026 availability of Foundayo transformed oral obesity treatment from a development-stage opportunity into a commercial market.

Oral medicines may be particularly relevant to:

• Patients reluctant to begin injections
• Primary-care prescribing
• Telehealth-led treatment
• Direct-to-patient pharmacy models
• Markets with limited injection-device infrastructure
• Maintenance treatment following initial weight reduction
• Combination regimens involving multiple oral medicines

However, daily dosing may create different adherence challenges from once-weekly injections.

Obesity Treatment Is Becoming the Primary Growth Engine

Incretin medicines were initially developed and commercialized primarily for type 2 diabetes. The market has since expanded rapidly into chronic weight management.

Growth is being supported by:

• Rising recognition of obesity as a chronic disease
• Greater clinical acceptance of pharmacological treatment
• Strong patient demand
• New oral formulations
• Broader specialist and primary-care participation
• Treatment of obesity-related complications
• Expansion of public and employer coverage
• Direct-to-patient distribution models

Obesity prescriptions are also creating demand for higher production volumes than many manufacturers originally planned for diabetes-only use.

Payer Access Determines Commercial Penetration

Regulatory approval defines whether a medicine can be marketed, but payer policy determines whether many patients can afford to begin and continue treatment.

Access decisions may include:

• Body mass index requirements
• Qualifying comorbidities
• Previous lifestyle intervention
• Step therapy
• Prior authorization
• Treatment-response requirements
• Prescriber restrictions
• Duration limits
• Continuation criteria

The Medicare GLP-1 Bridge illustrates the potential for public programs to expand access while retaining centralized eligibility and claims controls.

Outside the United States, access varies significantly. Some health systems reimburse incretin medicines for diabetes but exclude or tightly restrict the same active ingredient when prescribed for weight management.

Manufacturing Capacity Remains a Strategic Constraint

Incretin demand has placed pressure on active-ingredient capacity, sterile fill-and-finish operations, injection-device production and packaging.

Manufacturers must coordinate:

• Peptide active-ingredient production
• Vial or cartridge filling
• Pen assembly
• Needle and device supply
• Quality release
• Cold-chain logistics
• Country-specific packaging
• Inventory allocation

Lilly’s planned US$3.5 billion Pennsylvania facility demonstrates the scale of investment required to support next-generation injectable weight-management medicines.

The growth of small-molecule tablets may diversify the supply base. It can shift part of the market away from injectable-device bottlenecks and toward chemical synthesis, tablet production and conventional pharmacy distribution.

Multi-Receptor Agonists Intensify Product Competition

Single-receptor GLP-1 agonists established the modern incretin market. Competition is now moving toward medicines that activate two or three metabolic pathways.

Major development strategies include:

• GIP and GLP-1 dual agonism
• Glucagon and GLP-1 dual agonism
• GIP, GLP-1 and glucagon triple agonism
• GLP-1 and amylin combinations
• GLP-1 agonism combined with GIP receptor antagonism
• Oral combinations of incretin and non-incretin mechanisms

The objective is not simply to produce greater weight loss. Developers are attempting to differentiate products by:

• Glycaemic control
• Fat distribution
• Preservation of lean mass
• Liver-fat reduction
• Cardiovascular outcomes
• Dosing frequency
• Treatment maintenance
• Gastrointestinal tolerability
• Suitability for specific patient groups

Broader Indications Increase the Value of Established Molecules

Incretin medicines are being evaluated across a widening range of cardiometabolic conditions.

Commercially important indication groups include:

• Type 2 diabetes
• Obesity and overweight
• Cardiovascular risk reduction
• Obstructive sleep apnoea
• Metabolic dysfunction-associated steatohepatitis
• Heart failure
• Chronic kidney disease
• Other obesity-related complications

Zepbound is approved in the United States for chronic weight management and moderate-to-severe obstructive sleep apnoea in adults with obesity. Wegovy’s US label includes weight management and cardiovascular risk-reduction uses in defined populations.

Broader indications strengthen the clinical value proposition but also increase the need for outcomes data, specialist education and indication-specific payer policies.

Tolerability and Persistence Limit Real-World Value

Gastrointestinal adverse effects remain an important consideration across the incretin class. Dose escalation is commonly used to improve tolerability, but some patients discontinue treatment before reaching a maintenance dose.

Commercial performance will therefore depend on:

• Initiation rates
• Successful dose escalation
• Persistence
• Treatment re-entry
• Switching between products
• Management of adverse effects
• Patient education
• Affordability over extended treatment periods

A product generating strong trial outcomes may underperform commercially if patients cannot tolerate, obtain or remain on treatment.

Generic DPP-4 Competition Moderates Market Growth

DPP-4 inhibitors remain part of the incretin-based treatment landscape, particularly in type 2 diabetes.

Their advantages include:

• Oral administration
• Established prescribing experience
• Broad pharmacy availability
• Familiar safety profiles
• Generic or lower-cost options in many markets

However, the segment faces increasing competition from GLP-1 and dual-agonist medicines that offer stronger weight-management differentiation.

As patents expire, generic DPP-4 competition is expected to support treatment volumes while reducing revenue growth within the mature part of the market.

Unauthorized and Compounded Products Create Safety and Brand Risks

Rapid demand and periods of limited branded supply have contributed to the availability of unauthorized or compounded products.

Novo Nordisk has publicly warned about unauthorized semaglutide active ingredients and medicines, while the FDA maintains approved labeling and regulatory information for authorized products.

The market definition should exclude unapproved compounded products because their quality, ingredients and regulatory status differ from approved commercial medicines.

Market Segmentation Analysis

By Molecule Type

The market is segmented into:

• GLP-1 receptor agonists
• GIP and GLP-1 dual receptor agonists
• Glucagon and GLP-1 dual receptor agonists
• Triple and multi-receptor agonists
• DPP-4 inhibitors
• Incretin-based fixed-dose combinations

GLP-1 Receptor Agonists

GLP-1 receptor agonists currently form the largest segment.

The category includes established injectable therapies and newer oral products. Its commercial base spans type 2 diabetes, obesity, cardiovascular risk reduction and other cardiometabolic indications.

The segment is becoming more competitive following the approval of oral semaglutide for weight management and orforglipron in the United States.

GIP and GLP-1 Dual Agonists

Dual GIP and GLP-1 agonists are led commercially by tirzepatide, marketed for different indications under the Mounjaro and Zepbound brands.

Mounjaro is a peptide designed to activate both GIP and GLP-1 receptors.

The pipeline includes injectable and oral candidates such as enicepatide and VK2735.

Glucagon and GLP-1 Dual Agonists

This segment is designed to combine appetite and glucose effects from GLP-1 activity with the energy-expenditure and liver-related potential of glucagon-receptor activation.

Relevant programs include:

• Survodutide
• Mazdutide
• Pemvidutide and other clinical candidates

Survodutide produced positive Phase III obesity results in 2026, while mazdutide has received approvals in China for weight management and glycaemic control.

Triple and Multi-Receptor Agonists

Triple agonists target three metabolic pathways within a single medicine.

Retatrutide targets GIP, GLP-1 and glucagon receptors and is among the most prominent late-stage triple-agonist programs. Lilly’s planned Pennsylvania manufacturing facility is expected to support next-generation therapies including retatrutide.

This segment remains primarily pipeline-driven but may become an important source of market growth if late-stage programs achieve regulatory approval.

DPP-4 Inhibitors

DPP-4 inhibitors increase endogenous incretin activity by slowing the breakdown of GLP-1 and GIP.

The segment includes:

• Sitagliptin
• Linagliptin
• Saxagliptin
• Alogliptin
• Vildagliptin
• Other regional products

DPP-4 inhibitors remain important in oral type 2 diabetes treatment but face pricing pressure from generics and clinical competition from newer incretin agonists.

Fixed-Dose Combinations

Incretin-based fixed-dose combinations pair an incretin medicine with another diabetes treatment.

Common combination strategies include:

• DPP-4 inhibitor plus metformin
• DPP-4 inhibitor plus SGLT2 inhibitor
• GLP-1 receptor agonist plus basal insulin
• Future oral GLP-1 combinations
• GLP-1 and amylin combinations

Combination products can reduce the number of separate prescriptions but add formulation, pricing and reimbursement complexity.

By Molecular Format

The market is segmented into:

• Peptide-based drugs
• Non-peptide small-molecule drugs

Peptide-Based Drugs

Peptide drugs currently dominate the market.

The segment includes most approved GLP-1 receptor agonists, tirzepatide and many dual- or triple-agonist pipeline products.

Peptides are expected to retain a major position because of their established receptor activity, clinical validation and ability to support multi-receptor designs.

Non-Peptide Small Molecules

The non-peptide segment is expected to expand rapidly following the approval of Foundayo and the advancement of CT-996 and aleniglipron.

Small-molecule products may broaden oral access and reduce reliance on sterile injectable capacity. Their market penetration will depend on efficacy, safety, manufacturing economics, dosing convenience and reimbursement.

By Route of Administration

The market is segmented into:

• Injectable
• Oral

Injectable Incretin Drugs

Injectables currently account for the largest share of incretin-based drug revenue.

The segment includes:

• Once-daily injections
• Once-weekly injections
• Future monthly or less-frequent products
• Prefilled pens
• Single-dose devices
• Multi-dose devices

Once-weekly administration has established a strong balance between treatment convenience and sustained pharmacological activity.

Oral Incretin Drugs

The oral segment includes:

• DPP-4 inhibitors
• Oral peptide GLP-1 receptor agonists
• Oral small-molecule GLP-1 receptor agonists
• Future oral dual or multi-receptor medicines

The segment is expected to gain share as obesity prescribing expands into primary care, telehealth and direct-pharmacy channels.

Oral growth should not be interpreted as the immediate replacement of injectables. Different patients may prioritize efficacy, weekly dosing, tablet convenience, cost or tolerability differently.

By Indication

The market is segmented into:

• Type 2 diabetes
• Obesity and overweight
• Cardiovascular risk reduction
• Obstructive sleep apnoea
• Metabolic liver disease
• Other cardiometabolic conditions

Type 2 Diabetes

Type 2 diabetes remains a major commercial indication.

The segment includes GLP-1 receptor agonists, dual GIP/GLP-1 agonists, DPP-4 inhibitors and fixed-dose combinations.

Growth will be influenced by:

• Earlier use of incretin therapies
• Diabetes prevalence
• Cardiovascular and kidney outcomes
• Competition with SGLT2 inhibitors
• National treatment guidelines
• Generic DPP-4 availability
• Reimbursement criteria

Obesity and Overweight

Obesity and overweight are expected to represent the fastest-growing indication group.

Growth is supported by:

• Injectable and oral GLP-1 products
• Dual-agonist adoption
• Increasing treatment awareness
• Direct-to-patient channels
• Public reimbursement initiatives
• Greater recognition of obesity-related complications

The segment remains sensitive to affordability and payer restrictions.

Cardiovascular Risk Reduction

Cardiovascular outcome evidence provides an important means of differentiating incretin medicines from treatments positioned only around weight reduction or glycaemic control.

Products with cardiovascular indications may gain access through benefit categories that differ from weight-management-only coverage.

Obstructive Sleep Apnoea

The approval of Zepbound for adults with moderate-to-severe obstructive sleep apnoea and obesity established a new incretin-based treatment category.

This indication can expand collaboration among obesity specialists, sleep physicians, primary-care providers and payers.

Metabolic Liver Disease

Several incretin and multi-receptor products are being evaluated for metabolic liver diseases.

Future adoption will depend on histological outcomes, liver-related events, patient selection and competition with liver-directed medicines.

By Therapy Type

The market is segmented into:

• Monotherapy
• Combination therapy

Monotherapy

Monotherapy currently represents a major share of incretin-based use, particularly where a single product provides glycaemic, weight or cardiometabolic benefits.

Combination Therapy

Combination therapy includes:

• Incretin drug plus metformin
• Incretin drug plus insulin
• Incretin drug plus SGLT2 inhibitor
• GLP-1 plus amylin
• Dual- or triple-receptor agonists
• Oral incretin plus another oral metabolic medicine

Combination development is expected to intensify as companies attempt to improve efficacy without proportionally increasing dose-related adverse effects.

By Distribution Channel

The market is segmented into:

• Hospital pharmacies
• Retail pharmacies
• Online and direct-to-patient pharmacies
• Specialty pharmacies
• Other institutional channels

Retail Pharmacies

Retail pharmacies represent a central channel for diabetes and obesity prescriptions.

The expansion of oral products may increase retail participation because tablets can be dispensed without injection-device training.

Online and Direct-to-Patient Pharmacies

Digital prescribing and home-delivery models are becoming more important.

Foundayo was launched through LillyDirect alongside telehealth and retail availability, while Novo Nordisk has expanded self-pay and digital access models for its semaglutide portfolio.

These channels can improve convenience but require appropriate prescribing, patient verification, follow-up and safety monitoring.

Specialty and Hospital Channels

Specialty and hospital pharmacies remain important for:

• Complex comorbidities
• Initial treatment education
• High-risk patients
• Institutional payer arrangements
• Restricted-distribution products
• Indication-specific treatment programs

By Payer Type

The market is segmented into:

• Commercial and private insurance
• Public insurance
• Employer-sponsored programs
• Self-pay
• Other access programs

Commercial and Private Insurance

Commercial insurers represent a major source of access in the United States and other private-insurance markets.

Coverage is frequently controlled through prior authorization, preferred products and negotiated rebates.

Public Insurance

Public coverage varies significantly by country and indication.

Diabetes treatment is more widely reimbursed than weight management in many markets. Public programs may require defined comorbidities, specialist prescribing or evidence of unsuccessful lifestyle intervention.

Employer-Sponsored Programs

Employers are increasingly involved in obesity-treatment decisions because of the potential relationship among obesity, healthcare costs, productivity and long-term disease risk.

However, high prescription costs may lead employers to impose participation, monitoring or continuation requirements.

Self-Pay

Self-pay remains important where obesity medicines are excluded from insurance.

Manufacturer-supported direct pharmacy models and transparent cash prices are becoming more influential in this segment.

Regional Analysis

North America

North America, led by the United States, represents the most commercially advanced incretin-based drug market.

The region combines:

• High awareness of GLP-1 medicines
• Large diabetes and obesity treatment populations
• Strong commercial insurance participation
• Direct-to-patient distribution
• Multiple approved oral and injectable products
• Significant domestic manufacturing investment
• Advanced clinical-development activity

The US market was transformed in 2026 by the launch of Wegovy tablets, approval of Foundayo and introduction of the Medicare GLP-1 Bridge.

The oral market now includes two distinct formats:

• Oral peptide semaglutide
• Non-peptide small-molecule orforglipron

The United States also remains a central manufacturing location. Lilly plans to invest more than US$3.5 billion in a Pennsylvania facility for injectable medicines and devices, including next-generation weight-management therapies.

Despite strong demand, access remains uneven. Commercial insurers and public programs may impose prior authorization, clinical criteria or preferred-product requirements. Self-pay and direct-pharmacy models continue to serve patients without conventional obesity-drug coverage.

Canada follows a more centralized and province-influenced reimbursement model. Commercial potential depends on national approval, provincial formularies, private insurance and available supply.

Europe and Germany

Europe is a major incretin market supported by established diabetes treatment, expanding obesity recognition and centralized medicine approval through the European Medicines Agency.

In May 2026, the EMA’s human medicines committee recommended the oral Wegovy formulation for weight management. The European Commission approved it on July 15, 2026, making it the first oral GLP-1 weight-management treatment authorized in the EU.

EU authorization does not create uniform reimbursement. Pricing, health-technology assessment and coverage decisions remain largely national.

Germany illustrates this distinction. The German Federal Joint Committee has confirmed that medicines used for weight reduction, including Wegovy for that purpose, fall under a statutory exclusion from reimbursement by the country’s public health insurance system as lifestyle medicines.

Consequently, the same incretin molecule can face very different access conditions depending on whether it is prescribed for:

• Type 2 diabetes
• Weight management
• A recognized cardiovascular indication
• Another separately reimbursable condition

Germany remains strategically important because of its large pharmaceutical market, specialist-care network and proximity to European peptide, device and pharmaceutical manufacturing.

European growth will depend on:

• National reimbursement decisions
• Evidence of health-system savings
• Oral-product launches
• Local manufacturing capacity
• Public affordability negotiations
• Indication-specific access
• Competition among branded medicines

Asia-Pacific

Asia-Pacific is expected to expand through rising diabetes treatment, increasing obesity recognition, local drug development and improvements in reimbursement.

Japan

Japan has a structured and comparatively restrictive approach to pharmacological obesity treatment.

Wegovy is approved for obesity disease under defined clinical conditions. Japanese guidance limits eligible use to patients who meet specified body mass index, comorbidity and prior lifestyle-treatment requirements.

Japanese safety and appropriate-use guidance states that Wegovy and Zepbound were listed for obesity treatment in November 2023 and March 2025, respectively. The same guidance emphasizes that these products are intended for diagnosed obesity disease rather than cosmetic or general weight-loss use.

Mounjaro is approved in Japan for type 2 diabetes, and Lilly Japan has warned against its use outside the approved indication.

Japan’s market is shaped by:

• National Health Insurance pricing
• Strict indication criteria
• Qualified prescriber and institution requirements
• Post-marketing safety monitoring
• High diabetes-treatment demand
• Controlled obesity-drug access
• Strong domestic pharmaceutical distribution

Future growth may come from additional oral products, broader outcomes evidence and medicines suited to Japanese clinical and reimbursement requirements.

China

China is becoming an increasingly important incretin market through multinational launches and domestic innovation.

Innovent Biologics’ mazdutide received Chinese approvals for weight management and glycaemic control in 2025. Mazdutide is a dual glucagon and GLP-1 receptor agonist, giving China a domestically developed multi-receptor product.

China’s NMPA also approved efsubaglutide alfa, a long-acting GLP-1 receptor agonist, for blood-glucose control in adults with type 2 diabetes.

The 2025 national medical-insurance drug list became effective on January 1, 2026. China’s National Healthcare Security Administration requires nationally negotiated products to use defined payment standards, with local authorities responsible for implementation and patient cost-sharing.

China’s competitive landscape is influenced by:

• Large diabetes and metabolic-disease populations
• National reimbursement negotiations
• Provincial hospital access
• Domestic peptide-production capacity
• Local biotech innovation
• Increasing competition among GLP-1 and dual agonists
• Government oversight of pricing and procurement
• Commercial insurance for products outside public reimbursement

Local companies are expected to compete through differentiated targets, domestic pricing, manufacturing scale and inclusion in national or commercial insurance channels.

South America

South America represents an expanding but access-sensitive market.

Brazil is expected to remain the leading regional opportunity because of its population, diabetes burden, private healthcare sector and specialist network.

Regional constraints include:

• Uneven reimbursement
• Imported-product pricing
• Currency volatility
• Limited public obesity-drug coverage
• Supply concentration in major cities
• Variable availability of newer formulations

Oral small-molecule products may eventually improve distribution, but affordability will remain the central barrier.

Middle East and Africa

The Middle East and Africa market is expected to expand from a comparatively small base.

Growth will initially be concentrated in:

• Gulf Cooperation Council countries
• Private hospital networks
• Specialist diabetes and obesity centers
• Markets with high diabetes prevalence
• Self-pay and employer-supported channels

Novo Nordisk has identified the UAE among the initial international markets for the Wegovy pill, demonstrating the role of higher-income Middle Eastern markets in early oral-product expansion.

Across lower-income markets, access is likely to remain concentrated on diabetes treatment, mature DPP-4 inhibitors and selected lower-cost products.

Competitive Landscape

The competitive landscape is shifting from a small number of injectable GLP-1 medicines toward a diversified market involving oral peptides, oral small molecules, dual agonists, triple agonists and less-frequent injectable products.

Novo Nordisk

Novo Nordisk has one of the broadest commercial incretin portfolios.

Its major positions include:

• Ozempic injectable semaglutide for type 2 diabetes
• Rybelsus oral semaglutide for type 2 diabetes
• Wegovy injectable semaglutide for weight management
• Wegovy oral semaglutide for weight management
• Higher-dose injectable Wegovy
• CagriSema
• Zenagamtide

The Wegovy pill was launched in the United States in January 2026 and approved in the European Union in July 2026.

CagriSema combines semaglutide with the amylin analogue cagrilintide, while zenagamtide is a unimolecular GLP-1 and amylin receptor agonist in Phase III development.

Novo Nordisk’s strategy spans:

• Injectable and oral routes
• Diabetes and obesity
• Cardiovascular indications
• Peptide combinations
• Direct-pharmacy access
• Manufacturing expansion
• International launches

Eli Lilly

Eli Lilly competes through approved injectable and oral products and a broad multi-receptor pipeline.

Its portfolio includes:

• Mounjaro for type 2 diabetes
• Zepbound for obesity and obstructive sleep apnoea
• Foundayo oral orforglipron
• Retatrutide
• Other metabolic pipeline programs

Tirzepatide is a peptide that activates GIP and GLP-1 receptors.

Foundayo adds a non-peptide small-molecule oral GLP-1 product and gives Lilly commercial positions in both weekly injectable and daily oral obesity treatment.

The company’s planned Pennsylvania facility will support next-generation injectable treatments and devices, including retatrutide.

Roche

Roche is building a differentiated obesity and incretin portfolio around injectable dual agonists and oral small molecules.

Key programs include:

• Enicepatide, an injectable GLP-1/GIP dual agonist
• CT-996, an oral small-molecule GLP-1 receptor agonist
• Potential combination programs using metabolic and muscle-related mechanisms

Roche presented Phase II enicepatide data in 2026 and continues to list CT-996 among its expected clinical readouts.

The company’s strategy is designed to support multiple patient profiles rather than relying on a single route or mechanism.

Boehringer Ingelheim and Zealand Pharma

Boehringer Ingelheim and Zealand Pharma are developing survodutide, an injectable glucagon and GLP-1 dual agonist.

The Phase III SYNCHRONIZE-1 study reported positive results in April 2026, followed by additional obesity and liver-fat information in June 2026.

Survodutide’s competitive positioning emphasizes:

• Weight reduction
• Visceral-fat reduction
• Liver-fat reduction
• Metabolic health
• Potential use in obesity and liver-related disease

Amgen

Amgen is developing MariTide, or maridebart cafraglutide.

MariTide is an investigational peptide-antibody conjugate that combines GLP-1 receptor agonism with GIP receptor antagonism. It is administered monthly or potentially less frequently and is being studied in the Phase III MARITIME program.

Its less-frequent dosing model may differentiate it from daily oral and weekly injectable treatments.

Structure Therapeutics

Structure Therapeutics is developing aleniglipron, a once-daily oral non-peptide GLP-1 receptor agonist.

The company reported positive Phase IIb findings in 2026 and indicated that Phase III development was expected to begin in the third quarter of 2026.

Aleniglipron is positioned as a potential oral therapy with efficacy intended to compete with injectable products.

Viking Therapeutics

Viking Therapeutics is developing VK2735 as both an injectable and oral GIP/GLP-1 dual agonist.

The injectable formulation has entered a Phase III obesity program, while the oral formulation continues through clinical development.

A dual-route strategy could allow Viking to address different patient preferences and treatment stages.

Innovent Biologics

Innovent Biologics has established a commercial position in China with mazdutide.

Mazdutide is a glucagon and GLP-1 dual agonist approved in China for weight management and glycaemic control.

Innovent’s position demonstrates the growing importance of regional developers that can combine differentiated mechanisms with local clinical-development, manufacturing and reimbursement capabilities.

Other Relevant Market Participants

Established GLP-1 and Diabetes Companies

• AstraZeneca
• Sanofi
• Merck & Co.
• Boehringer Ingelheim
• Takeda Pharmaceutical
• Hanmi Pharmaceutical
• Tonghua Dongbao
• Jiangsu Hengrui Pharmaceuticals

Oral Small-Molecule Developers

• Eli Lilly
• Roche
• Structure Therapeutics
• AstraZeneca
• Pfizer and other companies maintaining early-stage metabolic research programs

Dual and Multi-Receptor Developers

• Eli Lilly
• Roche
• Boehringer Ingelheim
• Zealand Pharma
• Viking Therapeutics
• Innovent Biologics
• Altimmune
• Hanmi Pharmaceutical
• Sciwind Biosciences

DPP-4 Market Participants

• Merck & Co.
• Boehringer Ingelheim
• AstraZeneca
• Takeda Pharmaceutical
• Novartis
• Sanofi
• Generic pharmaceutical manufacturers

The competitive analysis should distinguish companies by:

• Approved versus investigational status
• Peptide versus small-molecule format
• Oral versus injectable route
• Receptor mechanism
• Indication
• Dosing frequency
• Manufacturing model
• Geographic rights
• Commercial access strategy

Key Developments

• In November 2024, Hanmi Pharm. Co., Ltd. has unveiled promising research on its novel obesity drug, HM17321, which not only promotes fat loss but also significantly boosts lean muscle mass, a major advancement over current GLP-1 therapies that can cause muscle loss during weight reduction. As a peptide-based treatment, HM17321 is expected to offer a more affordable and compatible option compared to costly antibody-based drugs like myostatin-targeting monoclonal antibodies, potentially transforming obesity management by preserving muscle while reducing fat.

The global incretin-based drugs market report delivers a detailed analysis with 59 key tables, more than 49 visually impactful figures, and 173 pages of expert insights, providing a complete view of the market landscape.